Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.85 EUR | +2.00% | +1.52% | +63.45% |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
Mar. 07 | Van Lanschot Kempen Plans Early Redemption of EUR100 Million Notes | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- This company will be of major interest to investors in search of a high dividend stock.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+63.45% | 1.85B | - | ||
+7.52% | 8.98B | B+ | ||
+10.85% | 3.41B | C- | ||
-30.01% | 3.31B | B | ||
+13.32% | 2.53B | B- | ||
+17.25% | 2.45B | C | ||
+45.87% | 2.22B | - | - | |
+27.98% | 1.72B | B+ | ||
+6.20% | 1.41B | B | ||
-19.47% | 930M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VLK Stock
- VA3 Stock
- Ratings Van Lanschot Kempen N.V